Walnut Cove, NC, United States of America

Julio A Munoz

This inventor holds 20 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Targacept, Inc., Oyster Point Pharma, Inc., Astrazeneca Ab. Active years: 1992-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julio A Munoz. Retrieved from https://idiyas.com/inventor/julio-a-munoz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 11)

% Patents Active = 45.0

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 236(Granted Patents)

Company Filing History:

Oyster Point Pharma, Inc.

R.j. Reynolds Tobacco Company

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2023

Loading Chart...

Areas of Expertise:

Synthesis

Salt Forms

Therapeutic Applications

Pyrimidine

Metanicotine

Benzamide

Polymorphs

Tobacco Extraction

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542253 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2023-01-03),

2. 10919879 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2021-02-16),

3. 10421745 - Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2019-09-24),

4. 9981949 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine (2018-05-29),

5. 9173876 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (2015-11-03),

6. 9145396 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine (2015-09-29),

7. 9107915 - Hydroxybenzoate salts of metanicotine compounds (2015-08-18),

8. 8901151 - Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2014-12-02),

9. 8846715 - (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof (2014-09-30),

10. 8778978 - Hydroxybenzoate salts of metanicotine compounds (2014-07-15),

11. 8633227 - Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine (2014-01-21),

12. 8604191 - Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine (2013-12-10),

13. 8580826 - Hydroxybenzoate salts of metanicotine compounds (2013-11-12),

14. 8541446 - (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof (2013-09-24),

15. 8476296 - Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide (2013-07-02),

Title: **Julio A. Munoz: Innovator in Pharmaceutical Synthesis**

Introduction

Julio A. Munoz, a distinguished inventor based in Walnut Cove, North Carolina, has made significant contributions to the field of pharmaceutical chemistry. With a portfolio encompassing 20 patents, his work primarily focuses on the synthesis of novel compounds that hold promise for therapeutic applications.

Latest Patents

Among Munoz's latest inventions is the patent for the "Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine." This invention details the stereospecific synthesis of the compound, along with its salt forms and unique polymorphic forms. The innovation aims to provide improved variants of this compound for potential use in medications.

Career Highlights

Munoz has held pivotal roles at several prominent companies in the pharmaceutical industry. Notably, he has worked with Targacept, Inc. and Oyster Point Pharma, Inc. His experience in these organizations has not only expanded his expertise but also enriched the fields of drug development and medicinal chemistry.

Collaborations

Throughout his career, Munoz has collaborated with talented individuals in the industry, including his coworkers Gary Maurice Dull and Srinivasa Rao Akireddy. These partnerships have fostered a collaborative environment for innovation and advanced research in pharmaceutical synthesis.

Conclusion

Julio A. Munoz continues to be a driving force in the realm of innovation, particularly within the pharmaceutical sector. His contributions through numerous patents showcase his dedication to developing new solutions that may enhance therapeutic capabilities. As he progresses in his career, Munoz's inventive spirit and commitment to advancing drug synthesis are sure to lead to further breakthroughs.

Profile summary based on public USPTO records.